Description

The pharmaceutical R&D expenditure market in China in terms of revenue is set to grow by US$ 34 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 16.8% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for pharmaceutical R&D expenditure. The China pharmaceutical R&D expenditure market is segmented on the basis of type. By type, it is categorized into clinical, discovery, and pre-clinical.

The report has profiled some of the key players of the market such as BeiGene Ltd., China Resources Pharmaceutical Group Limited, CSPC Pharmaceutical Group Limited, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shanghai Pharmaceuticals Holding Co. Ltd., Sino Biopharmaceutical Limited.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the pharmaceutical R&D expenditure market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: clinical, discovery, and pre-clinical
Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the China pharmaceutical R&D expenditure market
Pinpoint growth sectors and trends for investment
Understand what the future of the pharmaceutical R&D expenditure market in China looks like
Identify the competitive landscape and window of opportunity

Table of Contents

1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Pharmaceutical R&D Expenditure Market by Type
4.1 Clinical
4.2 Discovery
4.3 Pre-Clinical
5. Company Profiles
5.1 BeiGene, Ltd.
5.2 China Resources Pharmaceutical Group Limited
5.3 CSPC Pharmaceutical Group Limited
5.4 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.5 Shanghai Pharmaceuticals Holding Co., Ltd.
5.6 Sino Biopharmaceutical Limited
6. Appendix
6.1 About StrategyHelix
6.2 Disclaimer